PTPN5

PTPN5 (STEP) is a brain-enriched non-receptor protein tyrosine phosphatase that functions as a central brake on synaptic strengthening by dephosphorylating and inactivating kinases (ERK1/2, p38, Fyn, Pyk2) and promoting endocytosis of GluN2B-containing NMDA receptors and GluA2/GluA3-containing AMPA receptors through dephosphorylation of their regulatory tyrosine residues (PMID:22544749, PMID:30936304, PMID:21501258). STEP61 activity is suppressed by PKA phosphorylation at Ser221, calpain-mediated cleavage upon calcium influx, and oxidative stress-induced disulfide-bonded oligomerization, while its protein levels are controlled by ubiquitin–proteasome degradation mediated by parkin and regulated by PSD-95 (PMID:10537058, PMID:21198639, PMID:25583483, PMID:27457929). STEP knockout mice exhibit enhanced phosphorylation of ERK1/2, NR2B, and Pyk2, increased synaptic glutamate receptor expression, and improved hippocampal-dependent learning, establishing STEP as an in vivo opponent of long-term potentiation (PMID:21501258). Pathological elevation of STEP61—caused by impaired ubiquitin-proteasome degradation in Alzheimer's disease models or reduced NRG1-ErbB signaling in schizophrenia models—drives NMDA receptor internalization and cognitive or behavioral deficits that are reversed by genetic or pharmacological reduction of STEP activity (PMID:20427654, PMID:27752082).

1. 1999 High

   Establishing that STEP61 is subject to calcium-dependent proteolytic inactivation answered how excitatory signaling could rapidly terminate STEP phosphatase activity at synapses.

   Evidence In vitro calpain cleavage of purified STEP61, calcium ionophore/glutamate treatment of neurons with calpain inhibitor rescue

   PMID:10537058

   Open questions at the time

   • Precise cleavage site(s) and identity of the ~33 kDa fragment not fully mapped
   • Physiological contexts triggering calpain cleavage in vivo not defined
2. 2006 High

   Demonstrating that STEP directly binds and dephosphorylates NMDA receptors without other synaptic intermediaries established STEP as a first-order regulator of constitutive NMDAR surface trafficking.

   Evidence Direct pulldown binding assay, surface biotinylation, electrophysiology, and chronic STEP knockdown in neurons

   PMID:16819973

   Open questions at the time

   • Specific NMDAR subunit tyrosine residue dephosphorylated not identified in this study
   • Role of STEP in activity-dependent versus constitutive trafficking not separated
3. 2007 Medium

   Showing that STEP translation is co-induced by ERK/MEK and PI3K-mTOR downstream of β1-adrenergic stimulation revealed STEP as a negative-feedback element within kinase signaling cascades.

   Evidence Pharmacological blockade of translation, transcription, and MEK/PI3K/mTOR in corticostriatal slices and neuronal cultures

   PMID:17623046

   Open questions at the time

   • Translational control mechanism (mRNA elements, RNA-binding proteins) not identified
   • Feedback loop not validated with genetic approaches
4. 2010 High

   Linking Aβ to impaired ubiquitin–proteasome degradation of STEP61 and consequent NMDAR internalization provided a mechanistic basis for NMDAR hypofunction in Alzheimer's disease.

   Evidence Biotinylation, ubiquitin-conjugate IP, STEP-KO cortical cultures rescued from Aβ-induced NMDAR loss, Tg2576 mice, human AD brain lysates

   PMID:20427654

   Open questions at the time

   • E3 ligase mediating STEP61 ubiquitination in this context not identified (parkin link came later)
   • Whether STEP elevation alone is sufficient for cognitive decline not tested
5. 2011 High

   Generation and characterization of STEP knockout mice established that STEP tonically opposes synaptic strengthening in vivo, as its loss enhanced ERK/NR2B/Pyk2 phosphorylation, increased synaptic glutamate receptors, and improved hippocampal-dependent memory.

   Evidence STEP KO mice with behavioral testing, synaptosomal fractionation, and phospho-substrate immunoblotting

   PMID:21501258

   Open questions at the time

   • Contribution of individual STEP substrates to the cognitive enhancement not dissected
   • Compensatory phosphatase changes not fully ruled out
6. 2011 High

   Identifying oxidative-stress-induced disulfide bonding between Cys65 and Cys76 as a mechanism that oligomerizes and inactivates STEP61 revealed a redox switch controlling phosphatase activity, complementing the calpain and PKA regulatory axes.

   Evidence Site-directed mutagenesis of Cys residues, in vitro phosphatase assay with pNPP and ERK substrates, H2O2 treatment of neurons

   PMID:21198639

   Open questions at the time

   • Whether oxidative inactivation is reversible in neurons not shown
   • Structural basis of how oligomerization blocks catalysis not resolved
7. 2012 High

   Identifying Pyk2 as a direct STEP substrate dephosphorylated at Tyr402, with STEP also blocking Pyk2 translocation to the PSD, expanded STEP's substrate repertoire to a key integrator of calcium and adhesion signaling at synapses.

   Evidence In vitro dephosphorylation assay, co-IP, STEP KO mice, depolarization-induced translocation assay with subcellular fractionation

   PMID:22544749

   Open questions at the time

   • Whether STEP regulation of Pyk2 translocation is direct or secondary to dephosphorylation not resolved
   • In vivo behavioral consequence of STEP–Pyk2 axis not tested
8. 2014 Medium

   Demonstrating that PKA phosphorylation of STEP61 at Ser221 is modulated during motor skill learning and that intrastriatal PKA inhibition impairs learning linked STEP inactivation to real-time behavioral plasticity.

   Evidence Intrastriatal Rp-cAMPS injection, rotarod behavioral task, pSer221-STEP61 immunoblotting across brain regions

   PMID:24466306

   Open questions at the time

   • Causal link between pSer221-STEP61 change and motor learning relies on indirect pharmacology
   • Whether other PKA substrates contribute to the behavioral effect not controlled
9. 2015 Medium

   Showing that STEP61 mediates homeostatic synaptic scaling by bidirectionally regulating GluN2B and GluA2 phosphorylation in response to chronic activity changes positioned STEP as an effector of metaplasticity beyond Hebbian LTP/LTD.

   Evidence Chronic activity blockade/enhancement in hippocampal cultures, STEP61 overexpression rescue, tyrosine phosphorylation analysis

   PMID:26391783

   Open questions at the time

   • In vivo relevance of STEP-dependent homeostatic scaling not demonstrated
   • Upstream signal linking activity level to STEP61 abundance not identified
10. 2015 Medium

    Establishing that GABAergic tone maintains STEP61 in complex with ERK and Fyn, and that loss of inhibition frees these kinases to drive GluN2B phosphorylation and pain hypersensitivity, revealed STEP as a molecular gate between disinhibition and central sensitization.

    Evidence Intrathecal bicuculline/muscimol, co-IP for STEP–substrate complexes, STEP61 overexpression rescue in CFA inflammatory pain model, behavioral pain tests

    PMID:25478941

    Open questions at the time

    • Mechanism by which GABA-A signaling maintains STEP–substrate binding not defined
    • Single laboratory finding
11. 2015 High

    Identifying parkin as the E3 ubiquitin ligase that ubiquitinates STEP61 for proteasomal degradation—and showing that clinically relevant parkin mutants fail to do so—provided a mechanistic link between STEP61 accumulation and Parkinson's disease pathophysiology.

    Evidence In vitro ubiquitination assay, co-IP, PARK2-KO rat striatum, MPTP mouse model, human sporadic PD brain tissue

    PMID:25583483

    Open questions at the time

    • Functional consequence of STEP61 elevation on dopaminergic neuron survival not tested
    • Whether STEP61 accumulation contributes to cognitive symptoms in PD not addressed
12. 2016 High

    Demonstrating that PSD-95 binds STEP61, promotes its ubiquitination and degradation, and excludes it from the PSD revealed a scaffold-dependent mechanism that spatially restricts STEP activity to extrasynaptic compartments and protects synaptic NMDARs.

    Evidence Reciprocal co-IP, subcellular fractionation, PSD-95 KO mice, electrophysiology showing selective extrasynaptic NMDAR changes

    PMID:27457929

    Open questions at the time

    • Identity of the E3 ligase recruited by PSD-95 for STEP61 ubiquitination not determined
    • Whether PSD-95-dependent exclusion applies to AMPAR regulation by STEP not tested
13. 2016 High

    Showing that STEP61 is elevated in Nrg1+/- and ErbB2/4 schizophrenia models and in patient iPSC-derived neurons, and that genetic or pharmacological STEP reduction rescues NMDAR synaptic loss and behavioral deficits, established STEP as a convergent pathological node in schizophrenia.

    Evidence Nrg1+/- mice, CNS-specific ErbB2/4 mice, human iPSC-derived neurons, genetic STEP heterozygous KO rescue, STEP inhibitor, synaptic fractionation, behavioral assays

    PMID:27752082

    Open questions at the time

    • Mechanism linking reduced NRG1/ErbB4 signaling to impaired STEP degradation not identified
    • Whether STEP inhibition is therapeutic in patients remains untested
14. 2018 High

    Solving the crystal structure of a small-molecule fragment bound allosterically to STEP's phosphatase domain—confirmed by NMR—demonstrated that STEP can be pharmacologically modulated at a site distinct from the active site, opening a route to selective modulators.

    Evidence X-ray crystallography, 15N NMR, in vitro enzymatic assay, molecular dynamics simulations

    PMID:30207464

    Open questions at the time

    • Fragment is an activator rather than inhibitor; therapeutic utility for diseases of STEP excess requires inhibitory allosteric compounds
    • In vivo efficacy of allosteric modulators not demonstrated
15. 2019 High

    Identifying GluA2 and GluA3 AMPAR subunits as direct STEP binding partners whose synaptic levels are increased in STEP KO mice, and showing STEP promotes their lysosomal degradation, extended STEP's receptor-regulatory role beyond NMDARs to AMPARs and established a lysosomal trafficking mechanism.

    Evidence Mass spectrometry interactome, co-IP with GluA2/GluA3 C-termini, STEP-KO mouse fractionation, electrophysiology, STEP knockdown/overexpression in hippocampal slices

    PMID:30936304

    Open questions at the time

    • Tyrosine residue(s) on GluA2/GluA3 dephosphorylated by STEP not mapped
    • Pathway from STEP dephosphorylation to lysosomal sorting not mechanistically defined
16. 2019 High

    Demonstrating that STEP61 downregulation is both necessary and sufficient to gate BDNF-mediated GluN2B potentiation at spinal lamina I synapses—validated in ex vivo human dorsal horn—established STEP as a conserved checkpoint for pathological pain sensitization.

    Evidence Rodent inflammatory and neuropathic pain models, ex vivo human dorsal horn electrophysiology, gain/loss-of-function STEP61 manipulations

    PMID:31135041

    Open questions at the time

    • Mechanism of STEP61 downregulation downstream of KCC2-dependent disinhibition not fully resolved
    • Whether restoring STEP61 is analgesic in chronic pain patients unknown

• Key unresolved questions include the full structural basis for substrate selectivity among STEP's diverse targets, the identity of E3 ligases besides parkin that regulate STEP61 turnover in different brain regions, whether selective STEP inhibitors can reverse cognitive deficits in neurodegenerative and psychiatric diseases in humans, and the signaling logic that coordinates the multiple STEP inactivation mechanisms (PKA, calpain, oxidation) during distinct forms of plasticity.
• No structural model of STEP–substrate complex available
• Relative contributions of calpain, PKA, and oxidative inactivation during specific plasticity events not dissected
• Selective STEP inhibitors with in vivo CNS efficacy not yet reported